説明:
(abstract)Crush syndrome (CS) is characterised by ischaemia/reperfusion-induced rhabdomyolysis, leading to systemic inflammation and high mortality. Building on our previous findings that intravenous nitric oxide (NO) donors improve survival in this condition, we investigated the therapeutic efficacy of inhaled NO delivered via a portable, controlled-release device in an experimental rat model of CS. Anaesthetised rats underwent bilateral hindlimb compression using rubber tourniquets for 5 h, followed by reperfusion. Among the various inhalation conditions tested, administration of NO (160 parts per million) for 2 h after reperfusion significantly increased survival rate from 20 to 90%. Improvements in haemodynamic parameters, biochemical markers, and histopathological findings correlated with enhanced survival outcomes. These results suggest that on-site NO inhalation therapy may serve as an effective first-line, emergency intervention for CS, particularly in disaster settings.
権利情報:
キーワード: Crash syndrome, Nitric oxide
刊行年月日: 2026-03-12
出版者: bioRxiv
掲載誌:
研究助成金:
原稿種別: 査読前原稿 (Author's original)
MDR DOI:
公開URL: https://doi.org/10.64898/2026.03.09.710439
関連資料:
その他の識別子:
連絡先:
更新時刻: 2026-04-22 09:36:06 +0900
MDRでの公開時刻: 2026-04-22 12:24:42 +0900
| ファイル名 | サイズ | |||
|---|---|---|---|---|
| ファイル名 |
2026.03.09.710439v1.full.pdf
(サムネイル)
application/pdf |
サイズ | 1.82MB | 詳細 |